Passage BIO (PASG) Interest & Investment Income (2019 - 2025)
Passage BIO (PASG) posted quarterly Interest & Investment Income of -$8000.0 for Q1 2025, up 69.23% year-over-year from -$4727.3 in Q1 2024, and up 66.67% quarter-over-quarter from -$24000.0 in Q4 2024.
Passage BIO (PASG) Interest & Investment Income (2019 - 2025) Analysis & Trends
Passage BIO's Interest & Investment Income history runs 7 years deep, the most recent figure standing at -$8000.0 for Q1 2025.
- In Q1 2025, Interest & Investment Income rose 69.23% year-over-year to -$8000.0; the TTM figure through Dec 2025 stood at -$8000.0 (down 115.69% YoY), while the FY2025 annual figure was -$8000.0, down 115.69% from the prior year.
- Interest & Investment Income for Q1 2025 stood at -$8000.0, up from -$24000.0 in the prior quarter.
- The five-year high for Interest & Investment Income was $539000.0 in Q1 2023, with the low at -$921000.0 in Q1 2022.
- The 5-year median for Interest & Investment Income is $87000.0 (2023), against an average of $705.88.
- Peak annual rise in Interest & Investment Income reached 168.02% in 2022, while the deepest fall reached 1871.15% in 2022.
- Passage BIO's Interest & Investment Income stood at -$738000.0 in 2021, then surged by 168.02% to $502000.0 in 2022, then tumbled by 70.32% to $149000.0 in 2023, then slumped by 116.11% to -$24000.0 in 2024, then soared by 66.67% to -$8000.0 in 2025.
- Business Quant data shows PASG's Interest & Investment Income at -$8000.0 in Q1 2025, -$24000.0 in Q4 2024, and $99000.0 in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 67.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 27.90 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 28.14 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 115.94 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 10.98 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 5.13 Mn |
| 10 | Passage BIO | 13.99 Mn | 13.99 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | -8,000.00 |
| Dec 31, 2024 | -24,000.00 |
| Sep 30, 2024 | 99,000.00 |
| Jun 30, 2024 | 2,000.00 |
| Mar 31, 2024 | -26,000.00 |
| Dec 31, 2023 | 149,000.00 |
| Sep 30, 2023 | 148,000.00 |
| Jun 30, 2023 | 87,000.00 |
| Mar 31, 2023 | 539,000.00 |
| Dec 31, 2022 | 502,000.00 |
| Sep 30, 2022 | 110,000.00 |
| Jun 30, 2022 | -244,000.00 |
| Mar 31, 2022 | -921,000.00 |
| Dec 31, 2021 | -738,000.00 |
| Sep 30, 2021 | 186,000.00 |
| Jun 30, 2021 | 99,000.00 |
| Mar 31, 2021 | 52,000.00 |
| Dec 31, 2020 | -570,000.00 |
| Sep 30, 2020 | 99,000.00 |
| Jun 30, 2020 | 132,000.00 |